This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of +76.92% and +7.52%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
by Zacks Equity Research
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Smith+Nephew Stock May Gain From Strategic Deal With Standard Health
by Zacks Equity Research
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
by Zacks Equity Research
GEHC expands its bkPortfolio with the AI-powered bkActiv S Series to advance ultrasound-guided procedures.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma
by Zacks Equity Research
Veeva Systems launches China Campaign Manager to boost pharma engagement with localized, compliant CRM-driven solutions.
INBS Stock May Rise on SMARTOX Partnership Expanding Forensic Reach
by Zacks Equity Research
Intelligent Bio Solutions collaborates with SMARTOX to expand U.S. forensic reach, boosting its drug test tech and eyeing FDA clearance for growth.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
ZimVie Stock Gains Following the Launch of RealGUIDE Software Suite
by Zacks Equity Research
ZIMV launches RealGUIDE Software Suite and Implant Concierge in Japan to boost digital dental workflows.
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
by Zacks Equity Research
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
by Zacks Equity Research
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
by Urmimala Biswas
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
by Zacks Equity Research
HYPR secures FDA clearance for its next-gen Swoop system, advancing bedside MRI tech and reinforcing its mission to revolutionize accessible neuroimaging.
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
by Zacks Equity Research
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
by Zacks Equity Research
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
by Zacks Equity Research
Here is how AngioDynamics (ANGO) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.